Stephen Kanes - 02 Feb 2026 Form 4 Insider Report for Centessa Pharmaceuticals plc (CNTA)

Role
Chief Medical Officer
Signature
/s/ Raphael Deferiere, attorney-in-fact
Issuer symbol
CNTA
Transactions as of
02 Feb 2026
Net transactions value
$0
Form type
4
Filing time
03 Feb 2026, 19:03:56 UTC
Previous filing
04 Feb 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Kanes Stephen Chief Medical Officer C/O CENTESSA PHARMACEUTICALS PLC, 3RD FL., 1 ASHLEY RD, ALTRINCHAM, CHESHIRE, UNITED KINGDOM /s/ Raphael Deferiere, attorney-in-fact 03 Feb 2026 0001612859

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CNTA Ordinary Shares Award $0 +120,000 $0.000000 120,000 02 Feb 2026 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
F2 The shares reported in this transaction represent Restricted Share Units ("RSUs") issued under the Centessa Pharmaceuticals plc Amended and Restated 2021 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one Ordinary Share of the Issuer. The RSUs shall vest and be settled in four equal annual installments with the first such annual vesting being on February 2, 2027.

Remarks:

Exhibit 24.2 - Substitute Power of Attorney